RxDoctor Payments Data

Jaime Sale

Psychiatric/Mental Health · Rockingham, NCNPI 1437806775

Payments from drug & device makers

$2,834in general payments, 2019–2025

Across 106 payments — averaging $26.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$330
  • Supernus Pharmaceuticals, Inc.$318
  • Idorsia Pharmaceuticals US Inc$133
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60
  • Almatica Pharma LLC$50
  • plus $210 from 8 others

What the payments were for

  • Food & beverage$2,834100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,834 in reported general payments places this provider in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$25,138
Medicare patients
33
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl89$145,275
SpravatoEsketamine Hcl14$31,838
BelsomraSuvorexant18$7,902
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl48$7,208
Desvenlafaxine Succinate ErDesvenlafaxine Succinate65$3,727
Chlorpromazine Hcl14$2,487
Vilazodone Hcl31$1,938
Atomoxetine Hcl19$1,643
Duloxetine Hcl127$1,607
Quetiapine Fumarate71$1,241
Hydroxyzine Hcl44$1,044
Trazodone Hcl70$995
Amitriptyline Hcl54$944
Buspirone Hcl106$918
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine22$905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,733$145,27589 claims
Johnson & JohnsonSpravato$330$31,83814 claims
Almatica Pharma LLCSertraline Hcl$50$16457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Rockingham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →